Neurology

ACNS2321: A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas

Cancer Pediatrics Neurology Heart and Vascular Stroke Vascular Disease Pediatric Subjects Adult Subjects

This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Researchers want to see if lowering the dose of standard radiotherapy (RT) after chemotherapy can help get rid of CNS germinomas with fewer long-term side effects.

Vascular Mechanisms and Biomarkers of Stroke, Cognitive Impairment, and Other Neurological Disorders in People Living with HIV (PLWH) (Neurovascular Biomarkers in HIV): Carotid Artery Vessel Wall imaging (Pilot)

Neurology Heart and Vascular Immunology Infectious Disease Stroke Vascular Disease Immunodeficiency Viral Infectious Diseases Adult Subjects Female Subjects Male Subjects

Serum Biomarkers for Acute Ischemic and Hemorrhagic Strokes

Neurology Adult Subjects Female Subjects Male Subjects

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study of PGN-EDODM1 in Adult Participants with Myotonic Dystrophy Type 1 (FREEDOM2-DM1)

Neurology Pediatric Subjects Adult Subjects

The purpose of this study is to learn about the effects of an investigational medicine, PGN-EDODM1, to see how safe and tolerable multiple administrations of PGN-EDODM1 are for people with myotonic dystrophy type 1 (DM1) compared to placebo.

Linear predictive coding of EEG Activity for Diagnosis of Parkinson's Disease (LEAD-PD)

Neurology Adult Subjects Female Subjects Male Subjects

StrokeNet Thrombectomy Endovascular Platform (STEP)

Neurology Adult Subjects

FREQUENCY OF SELECTED SINGLE NUCLEOTIDE POLYMORPHISMS IN PHASE WITH THE MUTANT AND WILD-TYPE HTT ALLELES IN HUNTINGTON DISEASE GENE EXPANSION CARRIERS (WE45491)

Neurology Adult Subjects

Safety, Performance and Lesion Evaluation of Neurothrombectomy using CEREGLIDE 92 Intermediate Catheter: A Prospective Multi-Center Single-Arm IDE Trial (SPLENDID)

Neurology Adult Subjects

Combined Thrombectomy for Distal Medium Vessel Occlusion Stroke (DUSK Trial)

Neurology Stroke Adult Subjects Female Subjects Male Subjects

A phase III, randomized, multi-center, investigational, open label clinical trial that will examine whether treatment with endovascular thrombectomy is superior to standard medical therapy alone in patients who suffer a Distal Medium Vessel Occlusion Ischemic Stroke within 12 hours from time last seen well

Pridopidine EAP2

Neurology Adult Subjects

This EAP will provide access to pridopidine for up to 200 patients with ALS who are ineligible for clinical trials. Pridopidine will be given at a dose of 45 mg twice daily p.o. (or via feeding tube).

Each patient will be followed for 2 years with regularly scheduled visits. The screening and baseline visits will be performed in person; subsequent visits may occur in person or remotely. Recommended in-person visits will occur at Weeks 12, 52, 78, and end of treatment (Week 104 or early termination). If the patient is unable to complete the visits in person, these visits may also be completed remotely.

Attention Site Visitor